Epilepsy Nervous System Diseases Epilepsy
Conditions
Interventions
The patients were block-randomised (in blocks of ten) to receive blindly either active medication or placebo in pre-packed dispensers (Dosett), one for each of the 12 withdrawal weeks. Those randomise
Sponsors
Akershus University Hospital (Norway)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Epilepsy (minimum of two unprovoked epileptic fits) 2. Two year seizure freedom 3. Only one antiepileptic drug in use 4. Aged 18 to 67 years
Exclusion criteria
Exclusion criteria: 1. Juvenile myoclonus epilepsy 2. Paroxysmal EEG activity before termination of treatment, in patients with primary generalized epilepsy 3. Using several AEDs 4. Pregnancy 5. Mental retardation 6. Progressive neurological disease 7. Other known condition, which may affect patient's condition during follow-up 8. Other permanent medication (except in the case of contraceptive pills and hormonal treatment for menopausal conditions)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Neuropsychological function, as measured by a battery of 15 tests 2. Seizures | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Electrocardiogram (ECG) 2. Electroencephalogram (EEG) 3. Endocrine function 4. Quality of life 5. Blood lipid levels | — |
Countries
Norway
Outcome results
None listed